The project indicated that using a patient-partnered approach that leverages social media can potentially prevent the challenges often experienced when studying a rare cancer through traditional research models.
The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.
In a risk analysis, the FDA found that there is not sufficient evidence to support a causal relationship between radiofrequency exposure and tumorigenesis.
The FDA granted a priority review to Deciphera Pharmaceuticals’ new drug application for ripretinib to treat patients with advanced gastrointestinal stromal tumors.
Bristol-Meyers Squibb Company announced that the FDA granted a priority review to its BLA for liso-cel to treat patients with relapsed or refractory large B-cell lymphoma.
The planned trial will investigate the safety and efficacy of the novel multi-tumor associated antigen T-cell therapy in patients with post-transplant acute myeloid leukemia.
Researchers suggested that the receipt of 1, 2, or 3 doses of an HPV vaccine by females aged 15 to 19 years was associated with a lower incidence of preinvasive cervical disease when compared to unvaccinated females.
Janssen Pharmaceutical Companies submitted a supplemental biologics license application for daratumumab in combination with carfilzomib and dexamethasone to treat patients with relapsed/refractory multiple myeloma.
The FDA granted a priority review to capmatinib, a MET inhibitor being analyzed for the first-line treatment of previously treated patients with METex14-mutated advanced NSCLC.
Researchers highlighted the need for patient-reported outcomes data to provide valuable evidence in randomized-controlled trials of cancer treatment.